ONC BeOne Medicines Ltd.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1651308 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY32.9%
TTM net income YoY1,235.6%
TTM EPS YoY1,400.0%
Revenue 3-yr CAGR44.2%
Net income 3-yr CAGR—
Margins
Gross margin89.4%
Operating margin17.8%
Net margin13.9%
FCF margin21.9%
EBITDA margin20.2%
Returns
ROE18.4%
ROA10.5%
ROIC (approx.)158.2%
Asset turnover0.75x
Leverage & solvency
Liabilities / assets41.1%
Debt / equity0.18x
Current ratio3.55x
Interest coverage8.31x
Cash quality & payout
Operating cash flow / net income1.74x
Accruals ratio-7.7%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $5.34B | $3.81B |
| Gross profit | $4.67B | $3.22B |
| R&D expense | $2.15B | $1.95B |
| SG&A expense | $2.08B | $1.83B |
| Operating income | $447.14M | -$568.20M |
| Interest expense | $58.23M | $21.80M |
| Pretax income | $416.85M | -$533.00M |
| Income tax | $129.92M | $111.78M |
| Net income | $286.93M | -$644.79M |
| EBITDA | $588.82M | -$396.44M |
| EPS (basic) | 0.20 | -0.47 |
| EPS (diluted) | 0.19 | -0.47 |
| Weighted avg. shares (diluted) | 1.47B | 1.37B |
| Balance sheet | ||
| Cash & equivalents | $4.55B | $2.64B |
| Receivables | $865.08M | $676.28M |
| Inventory | $608.23M | $494.99M |
| Current assets | $6.23B | $3.99B |
| PP&E, net | $1.64B | $1.58B |
| Intangibles | $62.70M | $51.09M |
| Total assets | $8.19B | $5.92B |
| Current liabilities | $1.83B | $2.21B |
| Short-term debt | $57.29M | $851.53M |
| Long-term debt | $961.91M | $166.48M |
| Total debt | $1.02B | $1.02B |
| Total liabilities | $3.83B | $2.59B |
| Shareholders' equity | $4.36B | $3.33B |
| Net debt | -$3.53B | -$1.62B |
| Shares outstanding | 1.44B | 1.39B |
| Cash flow statement | ||
| Operating cash flow | $1.13B | -$140.63M |
| Capital expenditure | $185.84M | $492.66M |
| Free cash flow | $941.74M | -$633.29M |
| Investing cash flow | -$276.15M | -$548.35M |
| Financing cash flow | $1.06B | $193.45M |
| Depreciation & amortization | $141.69M | $171.76M |
| Stock-based compensation | $510.86M | $441.62M |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.